Open AccessOutcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan
Author(s) -
Saito Toshihiro,
Kitamura Yasuo,
Komatsubara Shuichi,
Matsumoto Yasuo,
Sugita Tadashi,
Hara Noboru
Publication year - 2006
Publication title -
asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.1111/j.1745-7262.2006.00175.x
Subject(s) - medicine , prostate cancer , urology , prostatectomy , survival rate , oncology , overall survival , prostate , gynecology , hormone therapy , stage (stratigraphy) , cancer , gastroenterology , biology , breast cancer , paleontology
Aim : To investigate the outcomes for Asian populations with locally advanced/clinical stage III prostate cancer (PCa) treated with currently prevailing modalities. Methods : We reviewed the record of 209 patients with clinical stage III PCa, who were treated at Niigata Cancer Center Hospital between 1992 and 2003. Treatment options included hormone therapy‐combined radical prostatectomy (RP+HT), hormone therapy‐combined external beam irradiation (EBRT+HT) and primary hormone therapy (PHT). Results : The 5‐ and 10‐year overall survival rates were 80.3% and 46.1% in all cohorts, respectively. The survival rates were 87.3% and 66.5% in the RP+HT group, 94.9% and 70.0% in the EBRT+HT group and 66.1% and 17.2% in the PHT group, respectively. A significant survival advantage was found in the EBRT+HT group compared with that in the PHT group ( P < 0.0001). Also, the RP+HT group had better survival than the PHT group ( P = 0.0107). The 5‐ and 10‐year disease‐specific survival rates for all cases were 92.5% and 80.0%, respectively. They were 93.8% and 71.4% in the RP+HT group, 96.6% and 93.6% in the EBRT+HT group and 88.6% and 62.3% in the PHT group, respectively. A survival advantage was found in the EBRT+HT group compared with the PHT group ( P = 0.029). No significant difference was found in disease‐specific survival between the EBRT+HT and RP+HT groups or between the RP+HT and PHT groups. Conclusion : Although our findings indicate that radiotherapy plus HT has a survival advantage in this stage of PCa, we recommend therapies that take into account the patients' social and medical conditions for Asian men with clinical stage III PCa.